Results 61 to 70 of about 6,042 (221)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis : the COMPASS analysis [PDF]

, 2020
Guselkumab is an interleukin-23 inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab.
Cameron, C., Diels, J., McElligott, S., Puig Sanz, Lluís, Schubert, A., Thilakarathne, P., Universitat Autònoma de Barcelona   +6 more
core   +1 more source

Clinical utility of guselkumab in the treatment of moderate-to-severe plaque psoriasis [PDF]

, 2021
Psoriasis is a chronic immune-mediated disease involving complex interaction of T cells and keratinocytes. The comprehensive pathogenesis of psoriasis is not fully under-stood but the IL-23/Th17 axis is a central pathway in driving disease development ...
Feldman, Steven R., Light, Jeremy G., Su, Jennifer J.   +2 more
core   +1 more source

Biologic treatments for psoriasis have different anatomical specificities in residual PASI

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI ...
Martina Burlando, Irene Schiavetti, Aurora Parodi, Emanuele Cozzani, Luca Mastorino, Eleonora Bongiovanni, Ilaria Salvi, Martina Del Vecchio, Paolo Dapavo   +8 more
wiley   +1 more source

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

RMD Open
Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA).Methods Post hoc analyses used data from ...
Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff   +10 more
doaj   +1 more source

CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo [PDF]

, 2018
Rare autosomal dominant mutations in the gene encoding the keratinocyte signaling molecule, Caspase Recruitment Domain-Containing Protein 14 (CARD14), have been associated with an increased susceptibility to psoriasis but the physiological impact of ...
Cheng, Phil, Contassot, Emmanuel, French, Lars E, Kiefer, Betina, Meier, Barbara, Mellett, Mark, Mohanan, Deepa, Nobbe, Stephan, Ospelt, Caroline, Satoh, Takashi K, Schairer, Rebekka, Thome, Margot   +11 more
core   +1 more source

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

International Journal of Dermatology, EarlyView.
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova, Daniela Pejrilova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Alena Machovcova, Petr Arenberger, Jiri Stork, Tomas Dolezal, Martin Tichy, the BIOREP study group, Zdenek Antal, Monika Balaz, Jirina Bartonova, Gabriela Behrami, Linda Blahova, Petr Bohac, Martin Cetkovsky, Dominika Diamantova, Magdalena Dobiasova, Olga Filipovska, Jana Foldesova, Martina Grycova, Eduard Hrnciř, Jiri Horazdovsky, Katerina Hrazdirova, Monika Hudymacova, Marie Jandova, Hana Janatova, Lucie Jaresova, Ludmila Kajtmanova, Frantisek Keznikl, Peter Kicko, Zuzana Kondasova, Sarka Kozojedova, Jiri Korda, Jana Kreisslova, Anezka Kreisslova, Silvie Krchova, Lenka Kulmanova, Natalie Kunesova, Zdenka Kysilka, Iva Lomicova, Romana Machackova, Barbora Machackova, Lukas Mericko, Miroslav Necas, Helena Nemcova, Radka Neumannova, Michaela Novakova, Jitka Osmerova, Veronika Pallova, Veronika Patavova, Lucie Petrů, Marie Policarova, Tomas Pospisil, Simona Risianova, Filip Rob, Marcela Rozkosova, Libuse Sazmova, Jaroslav Sevcik, Iva Schmidtmayerova, Martin Sicha, Kristyna Sokolova, Eliska Stankova, Jan Sternbersky, Ivana Strouhalova, David Stuchlik, Alena Stumpfova, Katerina Svarcova, Katerina Tepla, Hana Tomkova, Jana Tresnak Hercogova, Simona Vachatova, Yvetta Vantuchova, Ivana Vejrova, Iva Zampachova   +76 more
wiley   +1 more source

Safety of guselkumab in hepatitis B virus infection [PDF]

, 2019
Reactivation of hepatitis B virus (HBV) following the use of TNF antagonists has been reported and is a contraindication to use of these medications. Although the risk of reactivation of HBV during use of ustekinumab and secukinumab is low in patients ...
Duncan, James Robert, Elewski, Boni E., Orlowski, Timothy J.   +2 more
core  

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks

Rheumatology and Therapy
Introduction Studies evaluating the long-term comparative efficacy between biologic therapies for psoriatic arthritis (PsA) are scarce. Two biologic therapies, guselkumab and secukinumab, were evaluated up to 52 weeks in a mixed patient population ...
Suzy van Sanden, Agata Schubert, Barkha P. Patel, Miriam Zimmermann, Fareen Hassan   +4 more
doaj   +1 more source

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison [PDF]

Anais Brasileiros de Dermatologia
Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.
Leyla Baykal Selçuk, Hande Ermiş Akkuş, Burak Akşan, Deniz Aksu Arıca   +3 more
doaj   +1 more source

Efficacy and Safety of Oral Icotrokinra in Moderate‐to‐Severe Plaque Psoriasis: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

International Journal of Dermatology, EarlyView.
Meta‐analysis of randomized controlled trials demonstrates that oral icotrokinra significantly improves PASI responses in patients with moderate‐to‐severe plaque psoriasis, with early clinical benefit and a placebo‐comparable safety profile, supported by trial sequential analysis confirming robust and sufficient evidence.
Alhasan Altayf, Munder Lateiresh, Lutfiyah Marwan, Mohamed Yaseen Alfeetouri, Yassine Zouaoui, Muhammed Elhadi   +5 more
wiley   +1 more source